| 2.17 -0.08 (-3.56%) | 10-12 15:42 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.33 | 1-year : | 3.85 |
| Resists | First : | 2.85 | Second : | 3.29 |
| Pivot price | 2.54  |
|||
| Supports | First : | 2.14 | Second : | 1.78 |
| MAs | MA(5) : | 2.25 |
MA(20) : | 2.62 |
| MA(100) : | 2.68 |
MA(250) : | 2.43 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.2  |
D(3) : | 6.9 |
| RSI | RSI(14): 30.7 |
|||
| 52-week | High : | 3.72 | Low : | 1.7 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NKTX ] has closed above bottom band by 13.7%. Bollinger Bands are 17.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.31 - 2.33 | 2.33 - 2.34 |
| Low: | 2.1 - 2.12 | 2.12 - 2.14 |
| Close: | 2.22 - 2.25 | 2.25 - 2.28 |
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Sun, 04 Oct 2026
Nkarta (NKTX) Edges Higher to $2.58 as Traders Watch $2.45 Support and $2.71 Resistance - ATR Trailing Stop - https://www.siam.in/
Sun, 27 Sep 2026
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance - TradingView
Thu, 10 Sep 2026
Nkarta to Participate in September Investor Conferences - GlobeNewswire
Thu, 13 Aug 2026
Nkarta Inc (NASDAQ: NKTX) Stock Price, News & Analysis - Kalkine
Tue, 07 Jul 2026
Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth - Simply Wall Street
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 4.8 (%) |
| Held by Institutions | 82.7 (%) |
| Shares Short | 3,660 (K) |
| Shares Short P.Month | 3,440 (K) |
| EPS | -1.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.46 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.6 % |
| Return on Equity (ttm) | -38.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -93 (M) |
| Levered Free Cash Flow | -55 (M) |
| PE Ratio | -1.4 |
| PEG Ratio | 0 |
| Price to Book value | 0.63 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|